SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-156124
Filing Date
2022-05-20
Accepted
2022-05-20 16:05:09
Documents
15
Period of Report
2022-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d334855d8k.htm   iXBRL 8-K 31738
2 EX-1.1 d334855dex11.htm EX-1.1 195412
3 EX-5.1 d334855dex51.htm EX-5.1 12367
7 GRAPHIC g334855g69t87.jpg GRAPHIC 4682
  Complete submission text file 0001193125-22-156124.txt   433848

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA agle-20220520.xsd EX-101.SCH 2852
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20220520_lab.xml EX-101.LAB 18759
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20220520_pre.xml EX-101.PRE 11708
9 EXTRACTED XBRL INSTANCE DOCUMENT d334855d8k_htm.xml XML 3472
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 22947560
SIC: 2834 Pharmaceutical Preparations